Zobrazeno 1 - 2
of 2
pro vyhledávání: '"on behalf of PITER Collaborating group"'
Autor:
Quaranta M. G., Rosato S., Ferrigno L., Amoruso D. C., Monti M., Di Stefano P., Filomia R., Biliotti E., Migliorino G., Russo F. P., Degasperi E., Chemello L., Brancaccio G., Blanc P., Cannizzaro M., Barbaro F., Morsica G., Licata A., Kondili L. A., on behalf of PITER Collaborating group, Federico A., Dallio M., Loguercio C.
Publikováno v:
Antiviral therapy. 25(2)
Background In patients treated for HCV infection, potential drug–drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/grazoprevir (ELB/GZR) among co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f9d998e5f093d176ccab68c6bf50e6
https://pubmed.ncbi.nlm.nih.gov/32242526
https://pubmed.ncbi.nlm.nih.gov/32242526
Autor:
Kondili L. A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F. S., on behalf of PITER collaborating group, Federico A., Dallio M., Loguercio C.
Publikováno v:
Liver International
Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472cd83b37330413d69be24b22da73a1
http://hdl.handle.net/11392/2418641
http://hdl.handle.net/11392/2418641
